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Background
Cell line development (CLD) is a critical step in the gen-
eration of biotherapeutics, but it is still hindered by sev-
eral pain points, including the lengthy and labor-
intensive workflow needed to isolate desirable clones,
lack of reproducibility, as well as potential protein qual-
ity issues. Over the last decade, antibody titers in mam-
malian cell culture systems in excess of 3 g/L have been
achieved through the use of novel media and feeds.
However, it is still a challenge to consistently and
rapidly create a stable cell line and a cell culture process
capable of supporting both high antibody yield and
acceptable post-translational modifications while mana-
ging the effort required for execution of the workflow.
The goal of the study was to develop a robust and
reproducible stable cell line workflow to generate scal-
able high-producing clones in less than 6 months, with
industry-standard titers and desirable product quality
using minimal effort.
Using CHO-S™ as the host cell line, we first evalu-
ated if a single medium could be used for the entire
CLD workflow, therefore avoiding the issues and com-
plications of changing media during this process. We
investigated if a formulation previously shown to
increase titer as a production medium could in fact be
used for all CLD steps, from transfection to stable pool
isolation all the way through to clone productivity, with-
out compromising titers or performance. The same rich
production medium was used in limiting dilution
cloning and compared to a lean cloning medium proto-
type. Furthermore, robustness of the workflow was veri-
fied by testing multiple molecules. We also explored
reducing effort by streamlining all the steps of the work-
flow. Finally, we assessed top clone scalability and
expressed product quality. We tested whether clones
chosen only by titers responded well to scale-up and
process development in a model bioreactor setting. In
addition, product glycosylation from these clones was
compared to the same molecule produced in CHO
DG44 cells, a well-characterized production platform.
Results
Our results show that cell growth during selection and
productivity assessment were affected by both the basal
medium and nutrient feed strategy. Stable pools gener-
ated in either CD OptiCHO
TM Medium or CD Forti-
CHO
TM Medium gave the most desirable outcomes in
terms of recovery time and productivity. We also found
that CD FortiCHO
TM Medium can be used for every
step of the CLD workflow, including limiting dilution
cloning. When we performed a limiting dilution cloning
using the same pool seeded in either a lean cloning
medium prototype or in CD FortiCHO
TM Medium, we
found that the top 10 clones isolated from each medium
showed similar average titert r e n d s( F i g u r e1 ) .W ea l s o
established the robustness of the selection scheme by
demonstrating that all tested molecules show an
increase in cell pool titer during a two-stage selection
scheme that uses simultaneous puromycin and metho-
trexate treatment. In addition, the resulting clones can
readily be scaled up to bioreactors: clones that were pro-
ducing ~0.5 g/L in simple fed-batch (glucose feed only)
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any medium, provided the original work is properly cited.using shake flasks readily scaled-up to a DasGip bioreac-
tor and produced up to 3.2 g/L under fed-batch mode
with minimal process development (Table 1). Finally, we
demonstrated that the majority of clones isolated are
stable for productivity, and that the glycosylation pattern
of the same molecule produced in either CHO DG44 or
CHO-S
TM cells was indistinguishable.
Conclusions
T h eu s eo fas i n g l em e d i u mf o rt h ee n t i r ew o r k f l o wi s
revolutionary, and has the distinct advantage of avoiding
any need for media adaptation at any point in the work-
flow, whether it be preceding or following cloning, or
for productivity assessment. This in turn avoids any
undesirable genetic selection that may occur during
such adaptation steps, and facilitates streamlining the
workflow for ease of use and efficiency. Clones are easily
scaled from shake flask to bioreactor and produce 2-3 g/
L with minimal process development. Product glycosyla-
tion in top CHO-S
TM clones was comparable to histori-
cal data from CHO DG44-derived clones expressing the
same molecule. In addition, the establishment of clone
stability and acceptable glycosylation patterns are key
attributes required for regulatory approval of biothera-
peutic production. Together, these results demonstrate
the capabilities of the Freedom
TM CHO-S
TM Kit as an
efficient and robust stable CLD platform, which can be
accessed without the burden of milestone or royalty
payments.
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Figure 1 Cloning medium choice does not impact clonet i t e rd i s t r i b u t i o n .T h es a m eM o l e c u l e1 - p r o d u c i n gs t a b l ep o o l sw e r es e e d e df o r
limiting dilution cloning in either a lean cloning medium prototype or CD FortiCHO
TM Medium. Following clone scale-up, the top clones from
each process were assessed in shake flasks using a simple fed-batch process; day 7 data are shown. While there are differences in the absolute
numbers, especially for the top 3 clones, overall the clones produced similarly whether they were isolated from lean cloning medium prototype
or from CD FortiCHO
TM Medium.
Table 1 Molecule 1 clone productivity during scale-up from shake flask to bioreactor.
Molecule 1 clone Shake flask simple fed-batch (g/L) Shake flask fed-batch (g/L) Bioreactor fed-batch (g/L)
1 0.59 0.87 2.2
2 0.55 1.06 1.5
3 0.52 0.96 3.3
The top 3 clones expressing Molecule 1 were cultured in CD FortiCHO
TM Medium in shake flasks using a simple fed-batch or fed-batch process, and in a DasGip
bioreactor using a fed-batch process. Clone titers increased 3- to 6-fold from simple fed-batch shake flask culture to fed-batch bioreactor culture.
Sabourin et al. BMC Proceedings 2011, 5(Suppl 8):P102
http://www.biomedcentral.com/1753-6561/5/S8/P102
Page 2 of 2